Anti-IL17A Halts the Onset of Diabetic Retinopathy in Type I and II Diabetic Mice
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24021347 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Amy Y Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Diabetes Mellitus, Type 2, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, Cleveland Eye Bank Foundation, U.S. Department of Veterans Affairs.
Abstract (Originalsprache)
There are ~463 million diabetics worldwide, and more than half have diabetic retinopathy. Yet, treatments are still lacking for non-proliferative diabetic retinopathy. We and others previously provided evidence that Interleukin-17A (IL-17A) plays a pivotal role in non-proliferative diabetic retinopathy. However, all murine studies used Type I diabetes models. Hence, it was the aim of this study to determine if IL-17A induces non-proliferative diabetic retinopathy in Type II diabetic mice, as identified for Type I diabetes. While examining the efficacy of anti-IL-17A as a potential therapeutic in a short-term Type I and a long-term Type II diabetes model; using different routes of administration of anti-IL-17A treatments. Retinal inflammation was significantly decreased (p < 0.05) after Type I-diabetic mice received 1 intravitreal injection, and Type II-diabetic mice received seven intraperitoneal injections of anti-IL-17A. Further, vascular tight junction protein Zonula Occludens-1 (ZO-1) was significantly decreased in both Type I and II diabetic mice, which was significantly increased when mice received anti-IL-17A injections (p < 0.05). Similarly, tight junction protein Occludin degradation was halted in Type II diabetic mice that received anti-IL-17A treatments. Finally, retinal capillary degeneration was halted 6 months after diabetes was confirmed in Type II-diabetic mice that received weekly intraperitoneal injections of anti-IL-17A. These findings provide evidence that IL-17A plays a pivotal role in non-proliferative diabetic retinopathy in Type II diabetic mice, and suggests that anti-IL-17A could be a good therapeutic candidate for non-proliferative diabetic retinopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Science, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
- Louis Stokes Cleveland VA Medical Center, Cleveland, OH 44106, USA.
Förderung
- NEI NIH HHS
- Cleveland Eye Bank Foundation
- U.S. Department of Veterans Affairs
- CSRD VA
- NIH
Zitieren
APA
Zhou, A. Y., Taylor, B. E., Barber, K. G., Lee, C. A., Taylor, Z. R. R., Howell, S. J., & Taylor, P. R. (2023). Anti-IL17A Halts the Onset of Diabetic Retinopathy in Type I and II Diabetic Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021347
Vancouver
Zhou AY, Taylor BE, Barber KG, Lee CA, Taylor ZRR, Howell SJ, et al. Anti-IL17A Halts the Onset of Diabetic Retinopathy in Type I and II Diabetic Mice. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021347
BibTeX
@article{Zhou2023,
author = {Zhou, Amy Y and Taylor, Brooklyn E and Barber, Katherine G and Lee, Chieh A and Taylor, Zakary R R and Howell, Scott J and Taylor, Patricia R},
title = {Anti-IL17A Halts the Onset of Diabetic Retinopathy in Type I and II Diabetic Mice},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24021347}
}
EUVIMED